Gliclazide and Vasotec drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Gliclazide (gliclazide) and Vasotec (enalapril maleate). Common drug interactions include blood calcium increased among females and acute myocardial infarction among males.

The phase IV clinical study analyzes what interactions people have when they take Gliclazide and Vasotec. It is created by eHealthMe based on reports of 11 people who take the same drugs from the FDA, and is updated regularly.

What is Gliclazide?

Gliclazide has active ingredients of gliclazide. It is often used in diabetes. eHealthMe is studying from 28,131 Gliclazide users. Check the latest studies of Gliclazide.

What is Vasotec?

Vasotec has active ingredients of enalapril maleate. It is often used in high blood pressure. eHealthMe is studying from 14,646 Vasotec users. Check the latest studies of Vasotec.



On Jul, 17, 2026

11 people who take Gliclazide and Vasotec together, and have interactions are studied.

Gliclazide and Vasotec drug interactions.

What are the common drug interactions of Gliclazide and Vasotec, by gender? *:

female:

  1. Blood calcium increased
  2. Blood pressure diastolic decreased
  3. Cough
  4. Decreased activity
  5. Deep vein thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis)
  6. Intestinal obstruction
  7. Myocardial infarction (destruction of heart tissue resulting from obstruction of the blood supply to the heart muscle)
  8. Pneumonia
  9. Pneumonia aspiration (bronchopneumonia that develops due to the entrance of foreign materials into the bronchial tree)
  10. Pulmonary embolism (blockage of the main artery of the lung)

male:

  1. Acute myocardial infarction (acute heart attack)
  2. Dermatitis (inflammation of the skin resulting from direct irritation by an external agent or an allergic reaction to it)
  3. Henoch-schonlein purpura (inflammation of the blood vessels in the skin and other body organs)
  4. Convulsions (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled of muscles contract and relax rapidly and repeatedly)
  5. Dysphagia (a condition in which swallowing is difficult or painful)
  6. Hypoglycaemia (deficiency of glucose in the bloodstream)
  7. Hypoglycaemic coma (coma due to deficiency of glucose in the bloodstream)
  8. Insomnia (sleeplessness)
  9. Renal impairment (severely reduced kidney function)

What are the common drug interactions of Gliclazide and Vasotec, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

  1. Blood pressure diastolic decreased
  2. Cough
  3. Deep vein thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis)
  4. Myocardial infarction (destruction of heart tissue resulting from obstruction of the blood supply to the heart muscle)
  5. Pneumonia aspiration (bronchopneumonia that develops due to the entrance of foreign materials into the bronchial tree)
  6. Pulmonary embolism (blockage of the main artery of the lung)
  7. Pyrexia (fever)

40-49:

  1. Henoch-schonlein purpura (inflammation of the blood vessels in the skin and other body organs)

50-59:

  1. Acute myocardial infarction (acute heart attack)

60+:

  1. Dermatitis (inflammation of the skin resulting from direct irritation by an external agent or an allergic reaction to it)
  2. Asthenia (weakness)
  3. Pneumonia
  4. Renal impairment (severely reduced kidney function)
  5. Reticulocyte count decreased
  6. Blood calcium increased
  7. Convulsions (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled of muscles contract and relax rapidly and repeatedly)
  8. Decreased activity
  9. Dysphagia (a condition in which swallowing is difficult or painful)
  10. Hypoglycaemia (deficiency of glucose in the bloodstream)

What are the existing conditions these people have? *

  1. Osteoporosis (bones weak and more likely to break): 1 person, 9.09%
  2. Birth Control: 1 person, 9.09%
  3. Acromegaly (body produces too much growth hormone, leading to excess growth of body tissues): 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Gliclazide and Vasotec?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Gliclazide and Vasotec:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Gliclazide:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Vasotec:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Gliclazide and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Vasotec and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on gliclazide and enalapril maleate (the active ingredients of Gliclazide and Vasotec, respectively), and Gliclazide and Vasotec (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: